Status:
COMPLETED
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
Eligibility Criteria
Inclusion
- Inclusion criteria:
- healthy female and male subjects
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01195675
Start Date
August 1 2010
Last Update
July 28 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1245.16.1 Boehringer Ingelheim Investigational Site
Biberach, Germany